Sinclair registers cold-sore drug in the EU

UK-based drugmaker Sinclair Pharma says that it has successfully registered SPHR900 in the European Union. The product, which is intended to treat recurrent sores on the skin, mouth and lips caused by herpes simplex infection, has been listed as a Class IIa Medical Device.

Sinclair explained that SPHR900, which is designed to expedite the healing process, is composed of several plant-derived compounds that have demonstrated the ability to both inhibit HSV replication and reduce discomfort and inflammation.

The firm said that it would seek to commercialize the product in Europe through various marketing partnerships, and estimates that, at present, the over-the-counter HSV treatment market in Germany, the UK and France alone is worth $83.0 million a year.